Exagen Inc.
NASDAQ:XGN · NASDAQ Global Market
+$0.16 today
Vol 0.30M · Avg 0.39M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-114.3%
avg 25.7%
ROIC
-30.0%
avg -55.9%
ROA
-34.4%
avg -53.9%
Analysis
ROIC is currently the strongest return metric at -30.0% versus its period average of -55.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
John Aballi | Chief Executive Officer, President & Director | $795,100.00 | — | 41 | $175,000.00 | 0.72% |
Jeffrey G. Black | Chief Financial Officer & Corporate Secretary | $665,421.00 | — | 57 | $342,442.00 | 1.42% |
Prashanti Reddy | Chief Medical Officer | $626,623.00 | — | — | — | — |
Tina S. Nova | Executive Chairman of the Board of Directors | $125,000.00 | — | 72 | $13,500.00 | 0.06% |
Tina Jacobsen | Vice President of Investor Relations | — | — | — | $13,500.00 | 0.06% |
Michael Mahler | Chief Scientific Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
5
$679,767.81
Net Sentiment
$679,767.81
Net selling
Most Active
ABALLI JOHN
3 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 5 sells worth $679,767.81 over the last 12 months. That adds up to net selling of $679,767.81. ABALLI JOHN was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +106.3% | +11.1% (13yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +106.3% over three years. Forward estimates point to Revenue at +11.1% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
BioAge Labs, Inc.
NASDAQ:BIOA
$774.26M
Aclaris Therapeutics, Inc.
NASDAQ:ACRS
$532.51M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$352.09M
NeoGenomics, Inc.
NASDAQ:NEO
$286.99M
Sight Sciences, Inc.
NASDAQ:SGHT
$279.55M
Alpha Teknova, Inc.
NASDAQ:TKNO
$276.11M
Lifecore Biomedical, Inc.
NASDAQ:LFCR
$208.18M
Sanara MedTech Inc.
NASDAQ:SMTI
$198.49M
Stereotaxis, Inc.
AMEX:STXS
$178.37M
MDxHealth S.A.
MDXH
$28.45M
Who manages XGN?
Exagen Inc. (XGN) lists 6 active executives. The top listed executive is John Aballi, Chief Executive Officer, President & Director.
Are XGN insiders buying or selling?
Recent insider activity shows net selling of $1.04M.
Explore More
Continue the stock analysis
Jump to another research area for this company.